Publisher
Springer Science and Business Media LLC
Reference24 articles.
1. Gradishar WJ, Anderson BO, Aft R, et al. NCCN guidelines: breast cancer, version 1. 2018. 20 March 2018.
2. Shapiro-Wright HM, Julian TB. Sentinel lymph node biopsy and management of the axilla in ductal carcinoma in situ. J Natl Cancer Inst Monogr. 2010;2010(41):145–149.
3. Hwang ES, Hyslop T, Lynch T, et al. The COMET (Comparison of Operative to Monitoring and Endocrine Therapy) Trial: a phase III randomized trial for low-risk ductal carcinoma in situ (DCIS). BMJ. 2018;9:e026797.
4. Elshof LE, Tryfonidis K, Slaets L, et al. Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - The LORD study. Eur J Cancer. 2015;51(12):1497–510.
5. Francis A, Fallowfield L, Rea D. The LORIS Trial: Addressing overtreatment of ductal carcinoma in situ. Clin oncol (R Coll Radiol (Great Britain)). 2015;27(1):6–8.
Cited by
36 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献